Epitopea, a Cambridge, UK- and Montreal, Canada-based transatlantic cancer immunotherapeutics company, received a £500K Grant from Innovate UK.
The company was selected to receive funding from Innovate UK’s Cancer Therapeutics programme, which will provide a non-dilutive grant in support of research that is aimed at developing both therapeutic vaccines and T cell receptor-based therapies targeting antigens that are differentially presented by stromal cells.
Led by CEO Dr. Alan C. Rigby, Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped antigens that are broadly shared across multiple patients with the same tumor type.
The company has created an extensive library of novel CryptigenTM TSAs, discovered by its proprietary CryptoMapTM platform that leverages immunopetidomics, genomics, and a bioinformatics pipeline, allowing the identification of aberrantly-expressed, tumor-specific antigens (aeTSA’s) that are hidden within cancer’s ’junk’ DNA. These hidden CryptigenTM TSAs were first discovered through research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at the Université de Montréal.
FinSMEs
12/09/2024